logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Kinase Inhibitor class drugs

    FiltersReset Filters
    51 results

    • afinitor

      (everolimus)
      Novartis Pharmaceuticals Corporation
      Usage: AFINITOR is indicated for: advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women; progressive neuroendocrine tumors (PNET and non-functional GI/lung type); advanced renal cell carcinoma (RCC); TSC-associated renal angiomyolipoma; TSC-associated subependymal giant cell astrocytoma (SEGA); and partial-onset seizures related to TSC.

    • alecensa

      (ALECTINIB HYDROCHLORIDE)
      Genentech, Inc.
      Usage: ALECENSA is indicated for adjuvant treatment in adults with resected ALK-positive non-small cell lung cancer (NSCLC) and for the treatment of adult patients with metastatic ALK-positive NSCLC, both detected by an FDA-approved test.

    • alunbrig

      (brigatinib)
      Takeda Pharmaceuticals America, Inc.
      Usage: ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) confirmed by an FDA-approved test.

    • augtyro

      (repotrectinib)
      E.R. Squibb & Sons, L.L.C.
      Usage: AUGTYRO is indicated for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) and for patients aged 12 and older with NTRK gene fusion-positive solid tumors that are advanced or metastatic, or where surgery poses severe risk, and have limited treatment options.

    • ayvakit

      (avapritinib)
      Blueprint Medicines Corporation
      Usage: AYVAKIT® is indicated for adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) with PDGFRA exon 18 mutations, advanced systemic mastocytosis (AdvSM), and indolent systemic mastocytosis (ISM). It is not recommended for patients with platelet counts below 50 × 10⁹/L.

    • balversa

      (Erdafitinib)
      Janssen Products LP
      Usage: BALVERSA is indicated for treating adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with FGFR3 genetic alterations, following progression on at least one prior systemic therapy. Selection of patients must utilize an FDA-approved companion diagnostic. It is not recommended for those eligible for PD-1 or PD-L1 inhibitors.

    • bosulif

      (Bosutinib)
      Pfizer Laboratories Div Pfizer Inc
      Usage: BOSULIF is indicated for treating chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in adults and patients aged 1 and older, whether newly diagnosed or resistant/intolerant to prior therapies. It is also used for adult patients with accelerated or blast phases of Ph+ CML who are resistant/intolerant to prior treatments.

    • brukinsa

      (zanubrutinib)
      BEIGENE USA, INC.
      Usage: BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), relapsed or refractory marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and relapsed or refractory follicular lymphoma (FL) in combination with obinutuzumab.

    • cabometyx

      (cabozantinib)
      Exelixis, Inc.
      Usage: CABOMETYX is indicated for advanced renal cell carcinoma (RCC), both as a monotherapy and in combination with nivolumab. It is also used for hepatocellular carcinoma (HCC) after sorafenib treatment and for locally advanced or metastatic differentiated thyroid cancer (DTC) in patients 12 and older who are radioactive iodine-refractory.

    • calquence

      (acalabrutinib)
      AstraZeneca Pharmaceuticals LP
      Usage: CALQUENCE is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous stem cell transplantation, previously treated MCL patients, and those with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).